Skip to content

Janux Therapeutics, Inc.

JANX· NasdaqCore metricsCIK 1817713

Pharmaceutical preparations552 peers

Last sale
Oct 16, 2026 · -4.62%
Market cap
$1.01B
61.17M shares
Filings
443
$9.29M
Q3 2026−5.6% FY25 yoy
-$21.57M
Q3 2026N/M FY25 yoy
-$31.26M
Q3 2026N/M FY25 yoy
-$25.51M
Q3 2026derivedN/M FY25 yoy
-$0.34
Q3 2026N/M FY25 yoy
$41.82M
Q3 2026−87.8% FY25 yoy
$1.01B
—
43.4×
1.1×
-5.36%
—

Twelve months to Sep 30, 2026 · derived

Price

$16.5141.62%$11.77past year
Oct 16, 2026 · IEX last sale
Figure
Range
IEX last saleClose of record

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$10.00MFY 2025
$10.59M0FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$10,000,000reported
FY 20242024-12-31$10,588,000reported
FY 20232023-12-31$8,083,000reported
FY 20222022-12-31$8,612,000reported
FY 20212021-12-31$3,637,000reported
FY 20202020-12-31$0reported

Pharmaceutical preparations

Janux Therapeutics, Inc. is the 169th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Janux Therapeutics, Inc. · CIK 1817713 · Engraved from SEC EDGAR